Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 20/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3920664 | 0.82 | MLNR (0.51) | MLNRCYP3A4CYP2D6KCNH2CYP1A2 | |
| SCHEMBL1704149 | 0.82 | MLNR (1.00) | MLNRCYP3A4CYP2D6KCNH2 | |
| SCHEMBL3913651 | 0.81 | MLNR (0.44) | MLNRCYP3A4CYP2D6KCNH2CYP1A2 | |
| SCHEMBL4188248 | 0.80 | MLNR (0.75) | MLNRCYP3A4CYP2D6KCNH2CYP1A2 | |
| SCHEMBL1705080 | 0.80 | MLNR (0.70) | MLNRCYP3A4CYP2D6KCNH2CYP1A2 | |
| SCHEMBL1705081 | 0.76 | MLNR (0.64) | MLNRCYP3A4CYP2D6KCNH2 | |
| SCHEMBL3912866 | 0.76 | MLNR (0.42) | MLNRCYP3A4CYP2D6KCNH2CYP1A2 | |
| SCHEMBL3924957 | 0.74 | EPHX2 (0.38) | MLNR | |
| SCHEMBL14618671 | 0.73 | MLNR (0.84) | MLNRCYP3A4CYP2D6KCNH2CYP1A2 | |
| Camicinal SCHEMBL1703910 | 0.72 | MLNR (1.00) | MLNRCYP3A4CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1907374-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007012479-A2 | BENZYLPIPERAZINE DERIVATES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2007-02-01 | — | — | WO | disclosed |